The role of iron in neurodegeneration. Prospects for pharmacotherapy of Parkinson's disease

Drugs and Aging

Volumn 14, Issue 2, 1999, Pages 115-140

  Jellinger, Kurt A ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]METHYL] 3,4 DIHYDRO 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 6 OL; 21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; 21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE; ANTIOXIDANT; BETA CARBOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DEFEROXAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; GLUTAMATE RECEPTOR ANTAGONIST; GLUTATHIONE; IRON; IRON CHELATING AGENT; LAZAROID; LEVODOPA; MELANIN; MONOAMINE OXIDASE B INHIBITOR; NEUROMELANIN; NIFEDIPINE; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; SCAVENGER; TAMETRALINE; TIRILAZAD;

HUMAN; IRON METABOLISM; LIPID PEROXIDATION; MITOCHONDRIAL RESPIRATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; DRUG INTERACTIONS; FORECASTING; HUMANS; IRON; MELANINS; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 0032975570     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914020-00004     Document Type: Review

References (305)

1. Jellinger KA. Neuropathology of movement disorders. Neurosurg Clin N Am 1998; 9: 237-62
2. Paulus W, Jellinger K. The neuropathologic basis of different clinical subtypes of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50: 143-55
3. Ma SY, Röyttä M, Rinne JO, et al. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997; 151: 83-7
4. Lowe J, Lennox G, Leigh PN. Disorders of movement and system degenerations. In: Graham DI, Lantos PL, editors. Greenfield's neuropathology. 6th ed. London: E. Arnold, 1997: 280-366
5. Goedert M, Jakes R, Spillantini MG. Alpha-synuclein and the Lewy body. Neurosci News 1998; 1: 47-51
6. Perry R, McKeith J, Perry E. Dementia wilh Lewy bodies: the second most common cause of dementia? Neurosci News 1998; 1: 28-39
7. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998; 57: 334-7
8. Youdim MBH, Ben-Shachar D, Yehuda S, et al. The role of iron in the basal ganglion. Adv Neurol 1990; 53: 155-62
9. Riederer P, Youdim MBH. Iron in central nervous system disorders. Vienna-New York: Springer-Verlag, 1993
10. Youdim MBH, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993; 8: 1-12
11. Gerlach M, Ben-Shachar D, Riederer P, et al. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994; 63: 793-807
12. Gerlach M, Riederer P, Youdim MBH. Molecular mechanisms of neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv Neurol 1996; 69: 177-94
13. Good PF, Perl DP Olanow CW. Oxidative stress with emphasis on the role of LAMMA in Parkinson's disease. In: Connor JR, editor. Metal and oxidative damage in neurological disorders New York: Plenum Press, 1997: 277-94
14. Hirsch EC, Faucheux B, Damier P, et al. Neuronal vulnerability in Parkinson's disease. J Neural Transm 1997; 50 Suppl.: 79-88
15. Hirsch EC, Faucheux BA. Iron metabolism and Parkinson's disease. Mov Disord 1998; 12 Suppl. 1: 39-45
16. Owen AD, Schapiro AHV, Jenner P, et al. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and demen tia with Lewy bodies. J Neural Transm 1997; 51 Suppl.: 167-73
17. Cooper JM, Schapira AHV. Mitochondrial dysfunction in neurodegeneration [review]. J Bioenerg Biomembr 1997; 29: 175-83
18. Good PF, Olanow CW, Perl DP. LAMMA studies of iron, oxidative stress, and neuroprotective strategies in Parkinson's disease. In: Yasui M, Strong MJ, Ota K, et al., editors. Mineral and metal neurotoxicology. Boca Raton (FL): CRC Press, 1997; 379-90
19. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998; 44 Suppl. 1: S72-84
20. Connor JR. Evidence for iron mismanagement in the brain in neurological disorders. In: Connor JR, editor. Metal and oxidative damage in neurological disorders. New York: Plenum Press, 1997; 23-40
21. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990; 55: 16-20
22. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994; 7: 548-58
23. Youdim MBH, Riederer P. Understanding Parkinson's disease. Sci Am 1997; 267: 52-9
24. Logroscino G, Marder K, Graziano J, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997; 49: 714-7
25. Marder K, Logroscino G, Tang X, et al. Systemic iron metabolism and mortality from Parkinson's disease. Neurology 1998; 50: 1138-40
26. Qian ZM, Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain of neurodegenerative disorders. Brain Res Rev 1998; 27: 257-67
27. Beal MF. Mitochondrial, free radicals, and neurodegeneration. Curr Opin Neurobiol 1996; 6: 661-6
28. Jenner P, Olanow CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim MHB, editors. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996: 24-45
29. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998; 13 Suppl. 1: 24-34
30. Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996; 103: 987-1041
31. Koller WC. Neuroprotective therapy for Parkinson's disease. Exp Neurol 1997; 144: 24-8
32. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997; 49: S26-33
33. Olanow W, Jenner P, editors. Neuroprotection in Parkinson's disease. New York: Academic Press. In press
34. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-23
35. Götz ME, Künig G, Riederer P, et al. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 1994; 63: 37-122
36. Keyer K, Imlay JA. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci USA 1966; 93: 13635-40
37. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990; 87: 1620-4
38. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyorsine nitration catalysed by superoxide dismutase. Acta Biochem Biophys 1992; 298: 431-7
39. Smith MA, Richey PL, Sayre LM, et al. Widespread perioxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653-7
40. Beal MF. Excitoxicity and nitric oxide in Parkinson's disease patho genes. Ann Neurol 1998; 44 Suppl. I: S110-4
41. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 1996; 48: 1-19
42. Hastings TG, Zigmond MJ. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopaminc metabolites. J Neural Transm 1997; 49 Suppl.: 103-10
43. Kastner A, Hirsch EC, Lejeune O, et al. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to the neuromelanin content? J Neurochem 1992; 59: 1080-9
44. Uhl GR, Walther D, Mash D, et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994; 35: 494-8
45. German DC, Manaye KF, Sonsalia PK, et al. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism-sparing of calbindin-D (26k)-containing cells. Ann N Y Acad Sci 1992; 648: 42-62
46. Hirsch EC, Mouatt A, Thomasset M, et al. Expression of calbindin D (28K)-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution on Parkinson's disease. Neurodegeneration 1992; 1: 83-93
47. Castelnau PA, Garrett RS, Palinski W, et al. Abnormal iron deposition with lipid peroxidation in transgenic mice expressing interleukin-6 in the brain. J Neuropathol Exp Neurol 1998; 57: 268-72
48. Sofic E, Riederer P, Heinsen H, et al. Increase iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199-205
49. Sofic E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Ncurosci Lett 1992; 142: 128-30
50. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33: 305-10
51. Riederer P, Sofic E, Rausch W-D, et al. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 1989; 52: 515-20
52. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348-55
53. Sian J, Dexter DT, Lees AJ et al. Glutathion related enzymes in Parkinson's disease. Ann Neurol 1994; 36: 356-61
54. Spencer JPE, Jenner A, Butler J, et al. Evaluation of the pro-oxidant and antioxidant actions of I-dopa and dopamine in vitro: implications for parkinsons disease. Free Radic Res 1996; 24: 95-105
55. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect of dopamine oxidation. Brain Res Bull 1994; 33: 419-524
56. Mizuno Y, Matuda S, Yoshino H, et al. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994; 35: 204-10
57. Damier P, Hirsch EC, Zhang P, et al. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993; 52: 1-6
58. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 1989; 53: 692-7
59. Yoritaka A, Hattori N, Mori H, et al. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J Neurol Sci 1997; 148: 181-6
60. Radunovic A, Porto WG, Zeman S, et al. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex. Neurosci Lett 1998; 239: 105-8
61. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38-44
62. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992; 42: 2241-50
63. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemcial detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc Natl Acad Sci U S A 1996; 93: 2696-701
64. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994; 3: 197-204
65. Alam ZL, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: a selective increase of 8-hydroxyguanidine in substantia nigra. J Neurochem 1997; 69: 1196-203
66. Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823-7
67. Schapira AH, Mann VM, Cooper JM et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142-5
68. Schapira AH. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 1994; 9: 125-38
69. Janetzky B, Hauck S, Youdim MB, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994; 169: 126-8
70. Reichmann H, Janetzky B, Riederer P. Iron-dependent enzymes in Parkinson's disease. J Neural Transm 1995; Suppl. 46: 155-64
71. Swerdlow, RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40: 663-71
72. Mytilineou C, Radcliffe PM, Olanou CW. L-(-)-desmethyl-selegiline, a metabolite of L-(-)-desmethyl selegiline protects dopamine neurons from excitotoxicity in vitro. J Neurochem 1997; 68: 434-6
73. Han SK, Mytilineou C, Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501-10
74. Zeevalk GD, Bernard LP, Nicklas WJ. Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism. J Neurochem 1998; 70: 1421-30
75. Toffa S, Kunikowska GM, Zeng BY, et al. Glulathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm 1997; 104: 67-75
76. Schipper HM, Libermann A, Stopa EG. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 1998; 150: 60-8
77. Rouault TA, Klausner RD. Iron-sulfur clusters as biosensors of oxidants and iron. Trends Biochem Sci 1996; 23: 174-7
78. Shergill JK, Cammack R, Cooper CE. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. Biochem Biophys Res Commun 1996; 228: 298-305
79. Counihan TJ, Landwehrmeer B, Lücking CH, et al. Lipid peroxidation in Parkinson's disease, an immunohistochemical study [abstract]. Neurology 1997; 48: A202
80. Omar R, Smith M, Perry G, et al. Immunohistochemical evidence of oxidative stress in Parkinson's disease [abstract]. J Neuropathol Exp Neurol 1996; 54: 634
81. Castellani R, Smith MA, Richey PL, et al. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996; 737: 195-200
82. a Good PF, Hsu A, Werner P, et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998; 57: 338-42
83. Lyras L, Perry RH, Perry EK, et al. Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J Neurochem 1998; 71: 302-12
84. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998; 70: 268-75
85. Kienzl E, Puchinger L, Jellinger K, et al. The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci 1995; 134 Suppl.: 69-75
86. Chrichton RR. Inorganic biochemistry of iron metabolism. Chichester: Ellis Horwood Ltd, 1991
87. Morris CM, Candy JM, Keith A, et al. Brain iron homeostasis. J Inorg Biochem 1992; 47: 257-65
88. Joshi JG. Ferritin-intracellular regulator of metal avalaibility. In: Connor JR, editors. Metal and oxidative damage in neurological disorders. New York: Plenum Press, 1997: 131-48
89. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997; 1331: 1-40
90. Dwork AJ, Schon EA, Herbert J. Non identical distribution of transferrin and ferric iron in human brain. Neuroscience 1988; 27: 333-45
91. Jellinger K, Kienzl E. Iron deposits in brain disorders. In: Riederer P, Youdim MBH, editors. Iron in central nervous system disorders. Vienna: Springer-Verlag, 1993; 19-36
92. Connor JR, Boeshore KL, Benkovic SA, et al. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 1994; 37: 461-5
93. Martin WR, Ye FQ, Allen PS. Increasing striatal iron content associated with normal aging. Mov Disord 1998; 13: 281-6
94. Earle KM. Studies in Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed tissue. J Neuropathol Exp Neurol 1968; 27: 1-14
95. Sofic E, Paulus W, Jellinger K, et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brain. J Neurochem 1991; 56: 978-82
96. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative disease affecting the basal ganglia. Brain 1991; 114: 1953-75
97. Dexter DT, Jenner P, Schapira AH, et al. The Royal Kings and Queens Parkinson's Disease Research Group. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol 1992; 32 Suppl.: S94-100
98. Uitti RJ, Rajput AH, Rozdilsky B, et al. Regional metal concentrations in Parkinson's disease and control brains. Can J Neurol Sci 1989; 16: 310-31
99. Jellinger K, Paulus W, Grundke-Iqbal I, et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sec 1990; 2: 327-40
100. Aotsuka A, Shinoto H, Kitao K, et al. Iron distribution in the substantia nigra of parkinsonian brain: PIXE analysis [abstract]. Ann Neurol 1992; 32: 248
101. Hirsch EC, Brandel JP, Galle P, et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991; 56: 446-51
102. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 1992; 59: 1168-71
103. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neuruns of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain Res 1992; 593: 343-6
104. Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993; 4: 61-5
105. Rutledge JN, Hilal SK, Silver AJ, et al. Study of movement disorders and brain iron by MR. Am J Neurol Res 1987; 8: 397-411
106. De Volder AG, Francart J, Laterre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989; 26: 239-47
107. Chen JC, Hardy PA, Kucharczyk W, et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. Am J Neurol Res 1993; 14: 275-81
108. 2-weighted MRI at 3T. Magn Reson Med 1994; 32: 335-41
109. Gorrell JM, Ordridge RJ, Brown GG, et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995; 45: 1138-43
110. Ye FQ, Allen PS, Wayne Martin WR. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov Disord 1996; 11: 243-9
111. Aime S, Bergamasco B, Biglino D. EPR investigations of the iron domain in neuromelanin. Biochim Biophys Acta Mol Basis Dis 1997; 1361: 49-58
112. Bauminger ER, Barcikowska M, Friedman A. Does iron play a role in Parkinson's disease? Hyperfine Interact 1994; 91: 853-7
113. Galazka-Friedman J, Bauminger ER, Friedman A, et al. Iron in parkinsonian and control substantia nigra: a Mössbauer spectroscopy study. Mov Disord 1996; 11: 8-16
114. Lhermitte J, Kraus WM, McAlpine MA. On the occurence of abnormal deposits of iron in the brain in Parkinsonism with special reference to its localization. J Neurol Psychopathol 1924; 5: 195-208
115. Gerlach M, Trautwein AX, Zecca L, et al. Moessbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem 1995; 65: 923-6
116. Galazka-Friedman J, Friedman A. Controversies about iron in parkinsonian and control substantia nigra. Acta Neurobiol (Warsz) 1997; 57: 217-25
117. Gerlach M, Hirsch E, Jellinger K, et al. Iron in the parkinsonian substantia nigra. Mov Disord 1997; 12: 258-60
118. Olanow CW, Hauser RA. Magnetic resonance imaging in neurodegenerative diseases. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia (PA): WB Saunders, 1994: 445-69
119. Ryvlin P, Broussolle E, Piollet H, et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 1995; 52: 583-8
120. Schipper HM, Vinisky R, Brull R, et al. Astracyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998; 152: 188-96
121. Theil E. Regulation of ferritin and transferrin receptor mRNAs. J Biol Chem 1990; 265: 4771-4
122. Connor JR, Snyder BS, Arosio P, et al. A quantitative analysis of isoferrilins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995; 65: 717-24
123. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994; 36: 876-81
124. a Perez M, Valpueste JM, Degarcin EN, et al. Ferritin is associated with the aberrant tau-filaments present in progressive supranuclear palsy. Am J Pathol 1998; 152: 1531-9
125. Mash D, Pablo J, Buck B, et al. Distribution and number of tranferrin receptors in Parkinson's disease and in MPTP-trated mice. Exp Neurol 1991; 114: 73-81
126. Morris CM, Candy JM, Omar S, et al. Transferrin receptors in the Parkinsonian midbrain. Neuropathol Appl Neurobiol 1994; 20: 468-72
127. 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 1993; 60: 2338-41
128. Loeffler DA, Conner NR, Juneou P, et al. Transferrin and iron in normal, Alzheimer disease and Parkinson's disease brain regions. J Neurochem 1995; 65: 710-6
129. Mash DC, Singer J, Pablo J, et al. Differential regulation of iron storage and transport markers in Parkinson's disease. Neurology 1994; 44 Suppl. 2: 269
130. 125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys. Brain Res 1995; 691: 115-24
131. 52Fe)-citrate and positron emission tomography [abstract]. New Trends Clin Neuropharmacol 1994; 8: 130
132. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A 1995; 92: 9603-7
133. Leveugle B, Faucheux BA, Bouras C, et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 1996; 91: 566-72
134. 125I-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res 1997; 749: 170-4
135. Schipper HM, Wang X, Manganaro F. A mechanism for pathological glial iron sequestration in Parkinson's disease. Ann Neurol 1995; 38: A327
136. Blank CL, Lewis RJ, Lehr RE. 6-Hydroxydopamine and related catecholaminergic neurotoxins, molecular mechanisms. In: Kostrzewa RM, editor. Highly selective neurotoxins: basic and clinical applications. Totawa: Humana Press, 1998; 1-18
137. Hall S, Rulledge JH, Challert T. MRI brain iron and 6-hydroxydopamine experimental Parkinson's disease. J Neurol Sci 1992; 113: 198-208
138. He Y, Thong PSP, Lee T, et al. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study. Brain Res 1996; 735: 149-53
139. Oestreicher E, Sengstock GJ, Riederer P, et al. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994; 660: 8-18
140. Double KL, Maywald M, Schmittel M, et al. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 1998; 70: 2492-9
141. Monteiro HP, Winterbourn CC. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 1989; 38: 4177-82
142. Kumar R, Agarwal AK, Seth PK. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995; 64: 1703-7
143. Pezzella A, Dischia M, Napolitano A. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J Med Chem 1997; 40: 221-6
144. Glinka Y, Tipton KF, Youdim MB. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 1996; 66: 2004-10
145. Shoham S, Glinka Y, Tenne Z, et al. Brain iron: function and dysfunction in relation to cognitive processes. In: Hallberg L, Asp NG, editors. Iron nutrition in health and disease. London: John Libbey, 1996: 205-18
146. Ben-Shachar D, Eshei U, Finberg JPM, et al. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991; 56: 1441-4
147. Perumal AS, Gopal VB, Tordzro K, et al. Vitamin E attenuates the toxic effects of 6-hydroxydopamine of free radical scavenging systems in rat brain. Brain Res Bull 1992; 29: 699-701
148. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 1997; 104: 469-81
149. +) induces NADH-dependent superoxide formation, and enhances NADH-dependent lipid peroxidation in bovien heart submitochondríal particles. Biochem Biophys Res Commun 1990; 170: 1049-55
150. Cleeter MWJ, Cooper JM, Schapira AHV. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992; 58: 786-9
151. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals: possible participation of levodopa. Adv Neurol 1993; 60: 242-50
152. Youdim MBH, Glinka Y. Iron dependent mechanisms of dopaminergic toxicity of 6-hydroxydopamine. Biogen Amin 1996; 12: 181-90
153. Royland JE, Langston JW. MPTP: a dopaminergic neurotoxism. In: Kostrzewa RM, editor. Highly selective neurotoxins: basic and clinical application. Totawa: Humana Press, 1998: 141-94
154. Singer TP, Castagnoli N Jr, Ramsay RR, et al. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987; 49: 1-8
155. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998; 13 Suppl. 1: 35-8
156. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993; 61: 1191-06
157. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rats. Neurosci Lett 1993; 161: 121-3
158. Huguet F, Page G, Morel P, et al. MPTP toxicity in rat striatal slices: dopamine uptake alteration does not appear to be related to lipid peroxidation. Toxicology 1997; 122: 93-9
159. Cassarino DS, Fall CP, Swerdlow RH. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta Mol Basis Dis 1997; 1361: 49-58
160. Gerlach M, Götz M, Dirr A, et al. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. Neurochem Int 1996; 28: 41-9
161. Nakamura K, Wang WY, Kang UJ. The role of glutathione in dopaminergic neuronal survival. J Neurochem 1997; 69: 1850-8
162. + inhibition of complex I. J Neurochem. In press
163. Hantraye P, Brouielet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996; 2: 1017-21
164. Przedhorski S, Jackson-Lewis Y, Yokoyama R, et al. Role of neuronal nitric oxide in MPTP-induced domaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996; 93: 4565-71
165. Mochizuki H, Imai H, Endo H, et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced hemiparkinsonism in monkeys. Neurosci Lett 1994; 168: 251-3
166. Temlett JA, Landsberg JP, Watt F, et al. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian african green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 1994; 62: 134-46
167. Goto K, Mochizuki H, Imai H, et al. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res 1996; 724: 125-8
168. Anghileri LJ, Thouvenot P, Bertrand A. Effects of iron complexes on brain calcium homeostasis. Ann Clin Lab Sci 1997; 27: 210-5
169. + toxicity on striatal dopaminergic terminals. J Neurochem 1997; 68: 732-8
170. + toxicity in substantia nigra: protection by desferrioxamine. Brain Res 1997; 773: 76-81
171. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease [review]. Neurosci Biobehav Rev 1997; 21: 393-400
172. a Le WD, Jankovic J, Xie WJ, et al. Protection of 1-methyl-4phenylpyridium ion (MPP(+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett 1998; 224: 197-200
173. Blanchet PJ, Konitsiotis S, Hyland K, et al. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Exp Neurol 1998; 153: 214-22
174. Sengstock G, Olanow C, Menzies R, et al. Infusion of iron into the rat substantia nigra; nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993; 35: 67-82
175. Sziraki I, Hohana-Kumar KP, Rauhals P, et al. Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 1998; 85: 1101-11
176. Wesemann W, Blaschke S, Solbach M, et al. Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm Park Dis Dement Sect 1994; 8: 209-14
177. Ben-Shachar D, Youdim MBH. Intranigral iron injection induces behavioral and biochemical 'parkinsonism' in rats. J Neurochem 1991; 57: 2133-5
178. Sengstock GJ, Olanow CW, Dunn AJ. Striatal dopaminergic markers, nigral volume, and rorational behavior following iron infusion into the rat substantia nigra. Exp Neurol 1994; 130: 82-94
179. Arendash G, Sengstock G, Olanow C, et al. Intranigral iron infusion as a model for Parkinson's disease. In: Woodruff W, Nonneman A, editors. Toxin-induced models of neurological disorders. New York: Plenum Press, 1994: 175-212
180. Shen XN, Bryburst G. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of 1-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem Res Toxicol 1998; 11: 824-37
181. Michel PP, Vyas S, Agid Y. Toxic effects of iron for cultured mesencephalic dopaminergic neurons derived from rat embryonic brains. J Neurochem 1992; 59: 118-27
182. Sengstock GJ, Zawia NH, Olanow CW. Intranigral iron infusion in the rat: acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration. Biol Trace Elem Res 1997; 58: 177-95
183. Rauhala P, Lin AMY, Chiueh CC. Neuroprotection by S-nitroglutathione of brain dopamine neurons from oxidative stress. FASEB J 1998; 12: 165-73
184. Lan J, Jiang DH. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 1997; 104: 649-66
185. Bringmann G, God R, Feineis D, et al. The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm 1995; Suppl. 46: 235-44
186. Bringmann G, Feineis D, God R, et al. Neurotoxic effects on the dopaminergic system induced by Taclo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline), a potential mamalian alkaloid; in vivo and in vitro studies. Biogen Amines 1996; 12: 83-102
187. Leuschner J, Beuscher N, Zimmermann T, et al. Investigation on plasma levels of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline after oral administration of chloral hydrate in man. Arzneimittelforschung 1998; 48: 1-5
188. Rausch W-D, Abdel-Mohsen M, Koutsilieri E, et al. Studies of the potentially endogenous toxin TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline) in neuronal and glial cell cultures. J Neural Transm 1995; Suppl. 46: 255-63
189. Sontag K-H, Heim C, Sontag TA, et al. Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline) after subchronic treatment in rats. J Neural Transm 1995; Suppl. 46: 283-9
190. Grote C, Clement HW, Wesemann W, et al. Biochemical lesions of the nigrostriatal systems by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline) and derivates. J Neural Transm 1995; Suppl. 46: 275-81
191. +) and N-methyl-beta-carbolines? Biochem J 1993; 291: 673-6
192. Janetzky B, God R, Bringmann G, et al. α-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline, a new inhibitor of complex I. J Neural Transm 1995: Suppl. 46: 265-73
193. Wilson JX et al. TaClo has no toxic effects on the striato-nigral system. J Neurochem 1999. In press
194. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994; 59: 401-5
195. Enochs WS, Nilges MJ, Swartz HM. Purified human neuromelanin, synthetic
196. Enochs WS, Sama T, Zecca L, et al. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J Neural Transm Park Dis Dement Sect 1994; 7: 83-100
197. Zecca L, Parati E, Mecacci C, et al. The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1992; 1138: 6-10
198. Odh G, Carstam R, Paulson J, et al. Neuromelanin of the human substantia nigra: a mixed-type melanin. J Neurochem 1994; 62: 2030-6
199. Zecca L, Pietra R, Goj C, et al. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 1994; 62: 1097-101
200. Zecca L, Shima T, Stroppolo A. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996; 73: 407-15
201. Shima T, Sama T, Swartz HM. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 1997; 23: 110-9
202. Linert W, Jameson RF, Herlinger E. Complex formation followed by internal electron transfer: the reaction between L-dopa and iron (III). Inorg Chim Acta 1991; 187: 239-47
203. Linert W, Herlinger E, Jameson RF, et al. Dopamine, 6-hydroxydopamine, iron, and dioxygen: their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1996; 1316: 160-8
204. Jellinger K, Linert L, Kienzl E, et al. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm 1995; 46 Suppl.: 297-314
205. Korytowski W, Sama T, Zareba M. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. Arch Biochem Biophys 1995; 319: 142-8
206. Zareba M, Bober A, Korytowski W, et al. The effect of synthetic neuromelanin on yield of free hydroxyl radical generated in model systems. Biochim Biophys Acta 1995; 1271: 343-8
207. Hartley A, Cooper JJ, Schapira AHV. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res 1993; 627: 349-53
208. •OH) formation reflected by salicylate hydroxylation and neuromelanin: in vivo markers for oxidative injury of nigral neurons. Ann N Y Acad Sci 1993; 679: 370-5
209. Andrew R, Watson DG, Best SA, et al. The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem Res 1993; 18: 1175-7
210. Herrlinger E, Jameson RF, Linert W. The spontaneous autoxidation of dopamine. J Chem Soc Perkin Trans 1994; 2: 259-63
211. Galvani P, Colleoni M, Origgi M, et al. Mitochondrial toxicity of iron and the protective role of ferritin on dopaminergic PC12 cell lines. Toxicol Vitro 1995; 9: 365-8
212. Mochizuki H, Nishi K, Mizuno Y. Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture. Neurodegeneration 1993; 2: 1-7
213. Velez-Pardo C, Osirio MJ, Verschueren H, et al. Dopamine and iron induce apoptosis in PC 12 cells. Pharmacol Toxicol 1997; 80: 76-84
214. Offen D, Ziv I, Barzilai A, et al. Dopamine-melanin induces apoptosis in PC12 cells: possible implications for the etiology of Parkinson's disease. Neurochem Int 1997; 31: 207-16
215. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 26: 428-35
216. Ziv I, Zilkha-Falb R, Offen D, et al. Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997; 12: 17-23
217. Abbott RA, Cox M, Markus H, et al. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992; 46: 879-84
218. Cabrera-Valdivia F, Jimenez-Jimenez FJ. Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci 1994; 125: 82-6
219. Winsper SJ, Armstrong RA, Hodgkins PS, et al. Gallium-transferrin binding in treated and untreated Parkinson's disease. Neuroreport 1997; 8: 709-11
220. Ahlskog E, Uitti RJ, Low PA, et al. No evidence for systemic oxidant stress in Parkinson's disease or Alzheimer's disease. Mov Disord 1995; 10: 566-71
221. Logroscino G, Marder K, Graziano J, et al. Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord 1998; 13 Suppl. 1: 13-6
222. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-47
223. Shinoba LA, Beal MF. The role of oxidative processes and metal ions in aging and Alzheimer's disease. In: Connor JR, editor. Metal and oxidative damage in neurological disorders. New York: Plenum Press, 1997; 247-75
224. Arendash GW, Crandall BM, Kienzl E, et al. Neocortical iron levels in Alzheimer's disease correlate with neocortical lipid peroxidation and amyloid angiopathy. In: Collery P, Corbella J, Domingo JL, et al., editors. Metal ions in biology and medicine. Vol. 4. Paris: John Libbey Eurotext, 1996: 614-6
225. Perry G, Smith MA. A central role for oxidative damage in the pathogenesis and therapeutics of Alzheimer's disease. Alzheimer Dis ID Res Alert 1997; 2: 319-34
226. Contin M, Riva R, Albani F, et al. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996; 30: 463-81
227. Hughes AJ. Drug treatment of Parkinson's disease in the 1990s: achievements and future possibilities. Drugs 1997; 53: 195-205
228. Fahn S. Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997; 8: 376-93
229. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol 1993; 7: 121-8
230. Lange KW, Rausch WD, Gsell W. et al. Neuroprotection by dopamine agonists. J Neural Transm 1994; Suppl. 43: 183-201
231. Jenner P. The rationale for the use of dopamine agonists in parkinsons disease. Neurology 1995: Suppl. 45: 6-12
232. Tanaka M, Sotomatsu A, Yoshida T, et al. Inhibitory effects of bromocriptine on phospholipid peroxidation induced by dopa and iron. Neurosci Lett 1995; 183: 116-9
233. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996; 5: 369-88
234. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997; 49: S34-48
235. Balvi A, Ford B. Antiparkinsonian agents. CNS Drugs 1998; 9: 291-310
236. Sam EE, Verbeke N. Free radical scavenging properties of apomorphine enanatiomers and dopamine: possible implication in their mechanism of action in parkinsonism. J Neural Transm Park Dis Dement Sect 1995; 10: 115-27
237. Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 1996; 308: 219-25
238. Gassen M, Gross A, Youdim MBH. Apomorphine enantiomers protect pheochromocytma (PC12) cells from oxidative stress induced by hydrogen peroxide and 6-hydroxydopamine. Mov Disord 1998. In press
239. Gassen M, Gross A, Youdim MBH. Iron chelating, antioxidant, and cytoprotective properties of dopamine receptor agonist apomorphin. In: Olanow W, Jenner P, editors. Neuroprotection in Parkinson's disease. New York: Academic Press, 1998: In press
240. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamata neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998; 44: 110-9
241. Gupta M, Wiener HL. Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice. Neurochem Res 1995; 20: 385-9
242. + dopaminergic toxicity. J Neural Transm 1995; 100: 53-61
243. Thiffault C, Aumont N, Quirion R, et al. Effects of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 1995; 65: 2725-33
244. Magyar K, Szende B, Lengyel J, et al. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm 1998; 52: 109-23
245. Mytilineou C, Radcliffe P, Leonardi EK, et al. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity In vitro. J Neurochem 1997; 68: 33-9
246. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-83
247. Wiseman LR, McTavish D. Selegiline: a review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease. CNS Drugs 1995; 4: 230-46
248. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-7
249. Parkinson Study Group. Impact of deprenyl and tocopherol treatment in Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29-36
250. Ward C. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994; 57: 217-20
251. LeWitt P, Oakes D, Cui L, et al. The Parkinson Study Group. The need for levodopa as an end point of Parkinson's disease: progression in a clinical trial of selegiline and α-tocopherol. Mov Disord 1997; 12: 183-9
252. Shoulson I, Oakes D, Fahn S, et al. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998; 43: 318-25
253. Bentueferrer D, Menard G, Allain H. Monoamine oxidase B inhibitors: current status and future potential. CNS Drugs 1996; 6: 217-36
254. Cooper AJ, Carroll CB, Mitchell IJ. Glutamate antagonists for Parkinson's disease: rationale for use and therapeutic implications. CNS Drugs 1998; 9: 421-9
255. Komhuber J, Weller M, Schoppmeyer K, et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm 1994; Suppl. 43: 91-104
256. Lange KW, Riederer P. Glutamatergic drugs in Parkinson's disease. Life Sci 1994; 55: 2067-75
257. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46: 1551-6
258. Danysz W, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents: preclinical studies. Neurosci Biobehav Rev 1997; 21: 455-68
259. Montastruc JL, Rascol O, Senard JM. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci Biobehav Rev 1997; 21: 477-80
260. Blandini F, Greenamyre JT. Prospects of glutamate antagonists in the therapy of Parkinson's disease. Fundum Clin Pharmacol 1998; 12: 4-12
261. Loopuijt LD, Schmidt WJ. The role of NMDA receptors in the slow neuronal degeneration of Parkinson's disease. Amino Acids 1998; 14: 17-23
262. Benazzouz A, Boraud T, Dubedat P, et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 1995; 284: 299-307
263. Barneoud P, Maradier M, Miquet JM, et al. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 1996; 74: 971-83
264. McNeely W, Davis R, Entacapone. CNS Drugs 1997; 8: 79-88
265. Spencer CM, Benfield P. Tolcapone. CNS Drugs 1996; 5: 475-81
266. Nissinen E, Kaheinen P, Penttila KE, et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997; 340: 287-94
267. Miller JW, Seihub J, Joseph JA. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 1996; 21: 241-9
268. Acunacastroviejo D, Cotomontes A, Monti MG, et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1996; 60: PL23-9
269. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56: 359-84
270. Packer L, Landvik S. Vitamin E in biological systems. Adv Exp Med Biol 1990; 264: 93-103
271. Przedborski S, Jackson-Lewis V, Fahn S. Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov Disord 1995; 10: 312-7
272. Derijk MC, Breteler MMB, Denbreeijen JH, et al. Dietary antioxidants and Parkinson's disease: the Rotterdam study. Arch Neurol 1997; 54: 762-5
273. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-22
274. Dipaola R, Uitti RJ. Early detection of Parkinson's disease: implications for treatment. Drugs Aging 1996; 9: 159-68
275. Diamond SG, Markham CH, Hoehn MM, et al. Multi-center study of Parkinson's mortality with early versus late dopa treatment. Ann Neurol 1987; 22: 8-12
276. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990; 40: 265-9
277. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995; 10: 250-6
278. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 313: 1602-7
279. Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50: 858-63
280. Gassen M, Youdim MBH. The potential role of iron chelators in the treatent of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 1997; 80: 159-66
281. Cohen A. Current status of iron chelation therapy with desferrioxamine. Semin Hematol 1990; 27: 86-90
282. Ben-Schachar D, Youdim MBH. Iron, melanin and dopamine interaction: relevance to Parkinson's disease. Prog Neuropsychopharmacol 1993; 17: 139-50
283. Soriani M, Mazzuca S, Quaresima V, et al. Oxidation of desferrioxamine to nitroxide free radical by activated human neutrophils. Free Radic Biol Med 1993; 14: 589-99
284. Hartley A, Davies M, Rice-Evans C. Desferrioxamine as a lipid chain-breaking antioxidant in sickle erythrocyte membranes. FEBS Lett 1990; 264: 145-8
285. Darley-Usmar VM, Hersey A, Garland LG. A method for the comparative assessment of antioxidants as peroxyl radical scavengers. Biochem Pharmacol 1989; 38: 1465-9
286. Denicola A, Souza JM, Gatti RM, et al. Desferrioxamine inhibition of the hydroxyl radical-like reactivity of peroxynitrite: role of the hydroxamic groups. Free Radic Biol Med 1995; 19: 11-9
287. Braughler JM, Hall ED, Jacobsen EJ, et al. The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 1989; 14: 143-52
288. Braughler JM, Pregenzer JF. The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxyl radicals. Free Radic Biol Med 1989; 7: 125-30
289. Hall ED, McCall JM. Lazaroids: potent lipid peroxidation inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. In: Riederer P, Youdim MBH, editors. Iron in central nervous system disorders. Vienna: Springer Verlag, 1993: 173-88
290. Smith DH, Gennarelli TA, Mcintosh TK. The potential of 21-aminosteroids (lazaroids) as neuroprotective therapies in CNS injury. CNS Drugs 1995; 3: 159-64
291. Clark WM, Hazel JS, Coull BM. Lazaroids: CNS pharmacology and current research. Drugs 1995; 50: 971-83
292. Villa RF, Gorini A. Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol Rev 1997; 49: 99-136
293. Grasbon-Frodl EM, Nakao N, Brundin P. The lazaroid U-83836E improves the survival of rat embryonic mesencephalic tissue stored at 4°C and subsequently used for cultures or intracerebral transplantation. Brain Res Bull 1996; 39: 341-8
294. Grasbon-Frodl EM, Andersson A, Brundin P. Lazaroid treatment presents death of cultured rat embryonic mesencephalic neurons following glutathione depletion. J Neurochem 1996; 67: 1653-60
295. Grasbon-Frodl EM, Brundin P. Dopamin neuron death induced by congeners of nitrogen monoxide is prevented by the lazaroid U-83836E. Exp Brain Res 1997; 113: 138-43
296. Frodl EM, Nakao N, Brundin P. Lazaroids improve the survival of cultured rat embryonic mesencephalic neurons. Neuroreport 1994; 5: 2393-6
297. Nakao M, Frodl EM, Duan WM, et al. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 1994; 91: 12408-12
298. Björklund L, Vidal N, Stromberg I. Lazaroid-enhanced survival of grafted dopamine neurons does not increase target innervation. Neuroreport 1998; 9: 2815-9
299. Nakao N, Frodl EM, Widner H, et al. Over-expressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Med 1995; 1: 226-31
300. Othberg, Keep M, Brundin P, et al. Tirilazad mesylate improves survival of rat and human embryonic mesencephalic neurons in vitro. Exp Neurol 1997; 147: 498-502
301. Zhao WG, Richardson JS, Mombourquette MJ, et al. An in vitro EPR study of the free-radical scavenging actions of the lazaroid antioxidants U-74500A and U-78517F. Free Radic Biol Med 1995; 19: 21-30
302. Wesemann W, Soibach M, Nafe R, et al. Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism. J Neural Transm 1995; Suppl. 46: 175-82
303. Kupsch A, Gerlach M, Pupeter SC, et al. Pretreatment wich nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 1995; 6: 621-5
304. Wilson JX. Antioxidant defense of the brain: a role for astrocytes. Can J Physiol Pharmacol 1997; 75: 1149-63
305. Jameson GNL, Linert W. 6-hydroxydopamine, dopamine and ferritin: a cycle of reactions sustaining Parkinson's disease. In: Pli G, Cadenas E, Packer L, editors. Free radicals in brain pathophysiology. New York: Marcel Dekker. In press